

## TORGLIP 50

Abbreviated Prescribing information for Torglip (Vildagliptin tablets, 50mg) [Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

**PHARMACOLOGICAL PROPERTIES:** Torglip contains vildagliptin. Vildagliptin acts primarily by inhibiting DPP-4, the enzyme responsible for the degradation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

**INDICATIONS:** As an adjunct to diet and exercise to improve glycemic control in patients with type-II diabetes mellitus.

**DOSAGE AND ADMINISTRATION:** Administer orally with or just after food. Dosing must be individualized for patients with moderate or severe impaired renal function.

**WARNINGS & PRECAUTIONS:** Renal impairment, hepatic impairment, liver enzyme monitoring, cardiac failure, skin disorders, acute pancreatitis, hypoglycaemia.

**ADVERSE REACTIONS:** Hypoglycaemia, tremor, headache, chills, dizziness, fatigue, asthenia, nausea, diarrhoea, constipation, flatulence, gastro-oesophageal reflux disease, pancreatitis, weight increase, oedema peripheral, upper respiratory tract infection, nasopharyngitis, hyperhidrosis, Hepatitis (reversible upon discontinuation of the medicinal product), abnormal liver function tests (reversible upon discontinuation of the medicinal product), myalgia, arthralgia, urticarial, exfoliative and bullous skin lesions, including bullous pemphigoid.

### MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

Torrent Pharmaceuticals Ltd.

**IN/Torglip 50mg/JAN-20/01/ABPI**

(Additional information is available on request)